Research & Education

Subgroup of Patients with Small Cell Lung Cancer Defined

DENVER – The definition of distinct subgroups has not been as successful in small cell lung cancer (SCLC) as it has been in non-small cell lung cancer (NSCLC). Investigators have now described the clinical, pathologic, and molecular characteristics in a subgroup of SCLCs in never-smoking patients.

Additional Prognostic Variables Identified in Pleural Mesothelioma

DENVER – Refined models have been developed to better predict outcomes for patients with malignant pleural mesothelioma who are candidates for cytoreductive surgery. These prognostic models may provide a more accurate and minimally invasive method for predicting outcomes for patients who are surgical candidates, as well as determine patients who may benefit from chemotherapy.

Study Clarifies Molecular Mechanisms of RET Rearrangement

RET Fusion Occurs through Multiple Pathways

DENVER – Investigators have identified the molecular mechanisms underlying RET rearrangement, a genetic alteration recognized as a driver mutation in a small subset of lung adenocarcinoma.

ALK IHC Shown to Be Sensitive and Accurate in NSCLC

Findings Support Algorithmic Use of Test in Evaluation of NSCLC

DENVER – A new study shows that immunohistochemical (IHC) analysis is sensitive, specific, and accurate for detecting ALK protein expression based on gene rearrangement in non-small cell lung cancer (NSCLC).

ELCC 2014: Lung adenocarcinoma with RET fusion: early experience with diagnosis and targeted therapy


Drs. Oliver Gautschi and Lukas Bubendorf discourse on the presence of RET aberrations in NSCLC.

ELCC 2014: Late and Chronic Toxicities of New Targeted Therapies


Dr. Tony Mok, President of IASLC, offers an overview on most common toxicities related to targeted therapies in NSCLC.